Blogger Facebook Twitter You Tube RSS

Medical Antibacterial Compounds

Utah State University seeks a partner interested in licensing novel synthetic antibacterial compounds and a chemical platform for discovery of antibacterials utilizing previously successful aminoglycosides. Today, formerly effective antibiotics, such as, carbapenems, cephalosporins, aminoglycosides, and fluoroquinolones have been severely compromised by resistive bacterial. Multidrug resistance strains are emerging as natural, evolutionary bacterial response and in time can naturally defeat any antibiotic. Approximately 500,000 patients per year in American hospitals contract a Staphylococcal infection. Resistance is increasing to current antibiotics, among them are Linezolid (Zyvox- approved 2003, resistance reported 2007); and Daptomycin (Cubicin- approved 2003, resistance reported 2006). Both are inactive against G- bacteria. With the increasing reports on encountering Mecilline-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and vancomycin-resistant Staphlococcus aureus (VRSA), there is a need for new antibacterial agents that can treat the above resistive bacteria.
Features and Benefits
  • Treating Resistive Bacterial Infections:
    • MRSA (MIC=2-4 µ/mL)
    • VRE (MIC=2-4 µ/mL)
    • VRSA 
  • Assisting Immunosuppressive Conditions
  • Antibacterial discovery platform
  • Novel composition with no resistive bacterial evolution, creating greater effectiveness
  • Targets bacterial infection, decreasing resistive bacteria
  • Safe and versatile uses
  • New discovery platform, making antibiotic development cost-effective
The technology consists of novel therapeutic aminoglycoside compounds (neomycin derivatives) generated from a new simple and cost-effective chemistry platform. The new compounds open another strategy to combat the increasing problem of resistance, making it possible to revive the antibacterial activity of aminoglycoside using structural modifications that can alter the original mode of action. This is especially true for MRSA and VRE, which are known to exert a high level resistance to aminoglycosides. The discovery of two leads active against both MRSA and VRE is particularly significant since the transfer of resistance from enterococci to opportunistic S. aureus has been recognized as one of the stringent threats to public health.
Development Stage
The synthesis of highly active modified Neomycin compounds has been recently accomplished.  USU researchers are currently working to provide additional toxicity information on the lead compounds with mice model infection studies (bladder, kidney, etc.).
Patent Pending
Berry Treat
Senior Commercialization Associate
Life Sciences
(435) 797-4569
Reference: W08059